CLIMB BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
CLIMB BIO, INC. (CLYM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $6.40 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-05
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-12-31 was $53.00K, a 82.03% decline year-over-year.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-09-30 was $932.00K, a 30.35% increase year-over-year.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-06-30 was $5.40M, a 10696.00% increase year-over-year.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-03-31 was $17.00K, a 98.61% decline year-over-year.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $6.40M, a 180.46% increase from fiscal 2023.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $2.28M.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $457.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $985.00K derived: sum of 2 quarters · filed 2026-03-05 | $6.38M derived: sum of 3 quarters · filed 2026-03-05 | $6.40M 10-K · filed 2026-03-05 | $6.35M 10-K · filed 2025-03-25 |
| 2024-09-30 | $932.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $6.33M derived: sum of 2 quarters · filed 2024-11-12 | $6.35M 10-Q · filed 2024-11-12 | $6.64M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2024-06-30 | $5.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $5.42M 10-Q · filed 2024-08-14 | $5.71M derived: sum of 3 quarters · filed 2024-08-14 | $6.42M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2024-03-31 | $17.00K 10-Q · filed 2024-05-15 | $312.00K derived: sum of 2 quarters · filed 2024-05-15 | $1.03M derived: sum of 3 quarters · filed 2024-05-15 | $1.08M derived: sum of 4 quarters · filed 2024-05-15 | |
| 2023-12-31 | $295.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $1.01M derived: sum of 2 quarters · filed 2024-03-28 | $1.06M derived: sum of 3 quarters · filed 2024-03-28 | $2.28M 10-K · filed 2024-03-28 | |
| 2023-09-30 | $715.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $765.00K derived: sum of 2 quarters · filed 2023-11-14 | $1.99M 10-Q · filed 2023-11-14 | $1.99M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2023-06-30 | $50.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.27M 10-Q · filed 2023-08-10 | $1.27M derived: sum of 3 quarters · filed 2023-08-10 | $1.27M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2023-03-31 | $1.22M 10-Q · filed 2023-05-11 | $1.22M derived: sum of 2 quarters · filed 2023-05-11 | $1.22M derived: sum of 3 quarters · filed 2023-05-11 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $0.00 derived: sum of 2 quarters · filed 2023-03-06 | $0.00 10-K · filed 2023-03-06 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-15 | ||||
| 2021-12-31 | $307.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $307.00K derived: sum of 2 quarters · filed 2022-03-07 | $457.00K 10-K · filed 2022-03-07 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $150.00K 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $150.00K 10-Q · filed 2021-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |